Candela's ALEXlazr cleared by FDA:
This article was originally published in Clinica
Executive Summary
Candela's ALEXlazr has been cleared by the US FDA for treating pigmented skin lesions. Such lesions are commonly caused by sun exposure and sun damage. The device had previously been cleared for removing tattoos and pigmented dermal lesions. The treatment costs between $100 and $400 per session. The company based in Wayland, Massachusetts, estimates the potential worldwide market to be $2,000 million with over 28 million people in the US alone requiring the treatment.
You may also be interested in...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.
MAISI: Navigating The 'Valley Of Death' In Medtech Research Translation
Translating research from proof of concept to clinical investigations is a difficult hurdle to overcome. To succeed, researchers need to design their technology for industrial standard manufacturing early on, Anne Vanhoestenberghe, director for the Manufacture of Active Implants and Surgical Instruments (MAISI), told Medtech Insight.